Single Intradetrusor Injection Of Autologous Adipose-derived Stem Cells In Parkinson's Disease Patients With Overactive Bladder
Not Applicable
- Conditions
- Overactive Bladder
- Registration Number
- JPRN-UMIN000044106
- Lead Sponsor
- Al Zahraa Hospital
- Brief Summary
Patients received single intradetrusor ADSC injection experienced significant improvements in all bladder diary measures. Patients satisfaction with treatment, assessed by the mean of OAB-q SF total HRQL score significantly improved and symptom bother significantly decreased
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
patients with secondary parkinsonism syndromes, patients with polyuria with a daily urine volume more than 3000 mL, patients taking anticholinergic medications for OAB symptoms, history of benign prostatic hypertrophy, patients with stress urinary incontinence or urinary tract infection.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The change from baseline in OAB symptom score (OABSS) and the overactive bladder questionnaire short form (OAB-q SF) score in patients with Parkinson's disease
- Secondary Outcome Measures
Name Time Method The secondary outcomes were the change from baseline in the mean number of micturitions per 24 h, the mean number of urgency episodes per24 h, the mean number of urgency incontinence episodes per 24 h, and the mean number of nocturia episodes per night as recorded on a 3-day bladder diary at baseline and 6 months later. Safety assessments included any reported adverse events